Varex Imaging Corp (NASDAQ: VREX)

Sector: Healthcare Industry: Medical Devices CIK: 0001681622
Market Cap 564.17 Mn
P/B 1.18
P/E -8.33
P/S 0.66
ROIC (Qtr) -1.69
Div Yield % 0.00
Rev 1y % (Qtr) 4.90
Total Debt (Qtr) 395.50 Mn
Debt/Equity (Qtr) 0.83
Add ratio to table...

About

Varex Imaging Corporation, also known by its NASDAQ ticker symbol VREX, is a prominent player in the medical and industrial imaging sector. The company specializes in the design, manufacturing, and sale of X-ray imaging components, including X-ray tubes, flat panel and photon counting detectors, and related accessories. Varex Imaging Corporation operates in two primary segments: Medical and Industrial. In the Medical segment, Varex Imaging Corporation provides a variety of X-ray imaging components used in numerous medical imaging applications....

Read more

Investment thesis

Bull case

  • Healthy cash reserves of 119.50M provide 19.92x coverage of short-term debt 6M, demonstrating strong liquidity position and minimal refinancing risk.
  • Operating cash flow of 16.10M provides exceptional 53.67x coverage of minority interest expenses 300000, showing strong core operations.
  • Tangible assets of 884.90M provide exceptional 71.36x coverage of deferred revenue 12.40M, showing strong service capability backing.
  • Cash position of 119.50M provides exceptional 398.33x coverage of minority interest expenses 300000, indicating strong liquidity.
  • Tangible assets of 884.90M provide robust 11.33x coverage of other current liabilities 78.10M, indicating strong asset backing.

Bear case

  • Investment activities of 5.60M provide weak support for R&D spending of 89.30M, which is 0.06x, suggesting potentially insufficient investment in innovation relative to other capital deployment.
  • Operating cash flow of 16.10M provides insufficient coverage of deferred revenue obligations of 12.40M, which is 1.30x, raising concerns about future service delivery capabilities.
  • The company's operating cash flow of 16.10M shows concerning coverage of stock compensation expenses of 14.70M, with a 1.10 ratio indicating potential earnings quality issues.
  • Free cash flow of (13.30M) provides weak coverage of capital expenditures of 29.40M, with a -0.45 ratio suggesting additional external financing needs for growth initiatives.
  • Operating earnings of (23.90M) show weak coverage of depreciation charges of 26.90M, with a -0.89 ratio indicating high capital intensity and potential reinvestment needs.

Peer comparison

Companies in the Medical Devices
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 ABT Abbott Laboratories 173.80 Bn 32.73 5.47 12.94 Bn
2 SYK Stryker Corp 141.15 Bn 43.48 5.62 15.86 Bn
3 MDT Medtronic plc 123.47 Bn 25.92 3.55 29.10 Bn
4 BSX Boston Scientific Corp 112.80 Bn 38.92 5.62 11.44 Bn
5 EW Edwards Lifesciences Corp 45.66 Bn 33.38 7.76 0.70 Bn
6 DXCM Dexcom Inc 27.52 Bn 32.91 5.90 1.34 Bn
7 STE STERIS plc 24.13 Bn 34.08 4.14 2.05 Bn
8 PODD Insulet Corp 17.33 Bn 70.38 6.87 1.01 Bn

Industry comparisons

Current Valuation Value Ind Avg Percentile
EV to Assets EV to Assets 0.74 2.13
EV to Cash from Ops. EV/CFO 50.63 2.75
EV to Debt EV to Debt 2.06 17.25
EV to EBIT EV/EBIT -34.10 2.89
EV to EBITDA EV/EBITDA 246.99 4.53
EV to Free Cash Flow [EV/FCF] EV/FCF -61.28 29.36
EV to Market Cap EV to Market Cap 1.44 25.09
EV to Revenue EV/Rev 0.95 32.80
Price to Book Value [P/B] P/B 1.18 4.73
Price to Earnings [P/E] P/E -8.33 -2.04
Dividend Metrics Value Ind Avg Percentile
Dividend Coverage Ratio Dividend Coverage Ratio 0.00 40.22
Dividend Payout Ratio % Div Payout % (Qtr) 0.00 1.59
Dividend per Basic Share Div per Share (Qtr) 0.00 0.10
FCF Dividend Payout Ratio % FCF Div Payout % (Qtr) 0.00 -0.37
Interest Coverage Int. cover (Qtr) -0.70 196.93
Growth Metrics Value Ind Avg Percentile
Capex Growth (1y) % Capex 1y % (Qtr) -42.03 -152.08
Cash and Equivalents Growth (1y) % Cash & Equiv 1y % (Qtr) -60.40 8,476.58
Dividend Growth (1y) % Dividend Growth (1y) % 0.00 -0.44
EBIAT Growth (1y) % EBIAT 1y % (Qtr) 88.86 -792.16
EBITDA Growth (1y) % EBITDA 1y % (Qtr) -95.19 3.79
EBIT Growth (1y) % EBIT 1y % (Qtr) -162.08 -301.80
EBT Growth (1y) % EBT 1y % (Qtr) -876.00 -121.44
EPS Growth (1y) % EPS 1y % (Qtr) -33.88 -87.51
FCF Growth (1y) % FCF 1y % (Qtr) -151.55 10.43
Gross Profit Growth (1y) % Gross Profit 1y % (Qtr) 8.76 38.21
Liquidity Ratios Value Ind Avg Percentile
Asset Utilization Ratio Asset Util Ratio (Qtr) 0.78 0.55
Cash Payout Ratio Cash Payout (Qtr) 0.00 0.02
Cash Ratio Cash Ratio (Qtr) 0.73 1.80
Current Ratio Curr Ratio (Qtr) 3.89 4.18
Debt to Equity Ratio Debt/Equity (Qtr) 0.83 1.20
Interest Cover Ratio Int Coverage (Qtr) -0.70 196.93
Times Interest Earned Times Interest Earned (Qtr) -0.70 196.93
Profitability Value Ind Avg Percentile
EBITDA Margin % EBITDA Margin % (Qtr) 0.40 -2,396.63
EBIT Margin % EBIT Margin % (Qtr) -2.80 -2,478.60
EBT Margin % EBT Margin % (Qtr) -6.81 -2,690.42
Gross Margin % Gross Margin % (Qtr) 34.20 30.80
Net Profit Margin % Net Margin % (Qtr) -7.90 -2,821.53